Genomed Spólka Akcyjna
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. The last earnings update was 95 days ago. More info.
Add to Portfolio Compare Print
GEN Share Price and Events
7 Day Returns
1 Year Returns
GEN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Genomed Spólka Akcyjna (GEN) | -6.3% | -9.5% | -13.2% | 13.5% | 11.8% | 467.6% |
| PL Biotechs | 0.9% | -9.6% | -0.1% | -24.3% | -31.3% | 5.5% |
| PL Market | -0.9% | -7.1% | -6.3% | -7.4% | 9.6% | -11.5% |
1 Year Return vs Industry and Market
- GEN outperformed the Biotechs industry which returned -24.3% over the past year.
- GEN outperformed the Market in Poland which returned -7.4% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Genomed Spólka Akcyjna
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Genomed Spólka Akcyjna.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Extrapolated from most recent financials. | See below |
| Discount Rate (Cost of Equity) | See below | 11.8% |
| Perpetual Growth Rate | 10-Year PL Government Bond Rate | 2.9% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year PL Govt Bond Rate | 2.9% |
| Equity Risk Premium | S&P Global | 7.1% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.38 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.381 (1 + (1- 19%) (0%)) |
1.256 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.26 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.85% + (1.256 * 7.14%) |
11.81% |
Discounted Cash Flow Calculation for WSE:GEN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Genomed Spólka Akcyjna is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (PLN, Millions) | Source |
Present Value Discounted (@ 11.81%) |
|
|---|---|---|---|
| 2019 | 0.28 | Est @ 55.61% | 0.25 |
| 2020 | 0.39 | Est @ 39.78% | 0.31 |
| 2021 | 0.50 | Est @ 28.7% | 0.36 |
| 2022 | 0.61 | Est @ 20.95% | 0.39 |
| 2023 | 0.71 | Est @ 15.52% | 0.40 |
| 2024 | 0.79 | Est @ 11.72% | 0.40 |
| 2025 | 0.86 | Est @ 9.06% | 0.39 |
| 2026 | 0.92 | Est @ 7.19% | 0.38 |
| 2027 | 0.98 | Est @ 5.89% | 0.36 |
| 2028 | 1.02 | Est @ 4.98% | 0.34 |
| Present value of next 10 years cash flows | PLN3.59 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= PLN1.02 × (1 + 2.85%) ÷ (11.81% – 2.85%) |
PLN11.75 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= PLN11.75 ÷ (1 + 11.81%)10 |
PLN3.85 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= PLN3.59 + PLN3.85 |
PLN7.43 |
| Equity Value per Share (PLN) |
= Total value / Shares Outstanding
= PLN7.43 / 1.32 |
PLN5.62 |
| Calculation | Result | |
|---|---|---|
| Value per share (PLN) | From above. | PLN5.62 |
| Current discount | Discount to share price of
PLN21.00
= -1 x (PLN21.00 - PLN5.62) / PLN5.62 |
-273.4% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Genomed Spólka Akcyjna is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Genomed Spólka Akcyjna's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Genomed Spólka Akcyjna's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in PLN | PLN1.15 |
| WSE:GEN Share Price ** | WSE (2019-05-20) in PLN | PLN21 |
| Europe Biotechs Industry PE Ratio | Median Figure of 29 Publicly-Listed Biotechs Companies | 22.03x |
| Poland Market PE Ratio | Median Figure of 463 Publicly-Listed Companies | 10.7x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Genomed Spólka Akcyjna.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = WSE:GEN Share Price ÷ EPS (both in PLN) = 21 ÷ 1.15 |
18.21x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Genomed Spólka Akcyjna is good value based on earnings compared to the Europe Biotechs industry average.
- Genomed Spólka Akcyjna is overvalued based on earnings compared to the Poland market.
Price based on expected Growth
Does
Genomed Spólka Akcyjna's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 18.21x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts |
12.3%per year |
| Europe Biotechs Industry PEG Ratio | Median Figure of 23 Publicly-Listed Biotechs Companies | 1.29x |
| Poland Market PEG Ratio | Median Figure of 113 Publicly-Listed Companies | 0.93x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Genomed Spólka Akcyjna, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Genomed Spólka Akcyjna's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in PLN | PLN5.74 |
| WSE:GEN Share Price * | WSE (2019-05-20) in PLN | PLN21 |
| Poland Biotechs Industry PB Ratio | Median Figure of 8 Publicly-Listed Biotechs Companies | 1.84x |
| Poland Market PB Ratio | Median Figure of 689 Publicly-Listed Companies | 0.97x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = WSE:GEN Share Price ÷ Book Value per Share (both in PLN) = 21 ÷ 5.74 |
3.66x |
* Primary Listing of Genomed Spólka Akcyjna.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Genomed Spólka Akcyjna is overvalued based on assets compared to the PL Biotechs industry average.
Value checks
We assess Genomed Spólka Akcyjna's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Genomed Spólka Akcyjna has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
- No analysts cover Genomed Spólka Akcyjna, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Genomed Spólka Akcyjna's earnings growth is expected to exceed the low risk savings rate of 2.9%.
Growth vs Market Checks
- Genomed Spólka Akcyjna's earnings growth is expected to exceed the Poland market average.
- Unable to compare Genomed Spólka Akcyjna's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| WSE:GEN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts | 12.3% |
| Europe Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 20% |
| Europe Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 14.3% |
| Poland Market Earnings Growth Rate | Market Cap Weighted Average | 10% |
| Poland Market Revenue Growth Rate | Market Cap Weighted Average | 5.5% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Date (Data in PLN Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 19 | 1 | 2 |
| 2018-09-30 | 18 | 2 | 2 |
| 2018-06-30 | 17 | 2 | 2 |
| 2018-03-31 | 17 | 1 | 2 |
| 2017-12-31 | 16 | 1 | 2 |
| 2017-09-30 | 16 | 0 | 1 |
| 2017-06-30 | 16 | 0 | 1 |
| 2017-03-31 | 15 | 1 | 0 |
| 2016-12-31 | 14 | 1 | 0 |
| 2016-09-30 | 14 | -1 | 1 |
| 2016-06-30 | 12 | 0 | 1 |
| 2016-03-31 | 11 | 1 | 0 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
All data from Genomed Spólka Akcyjna Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in PLN Millions) | EPS * |
|---|---|
| 2018-12-31 | 1.15 |
| 2018-09-30 | 1.30 |
| 2018-06-30 | 1.69 |
| 2018-03-31 | 1.70 |
| 2017-12-31 | 1.36 |
| 2017-09-30 | 0.73 |
| 2017-06-30 | 0.51 |
| 2017-03-31 | 0.20 |
| 2016-12-31 | 0.21 |
| 2016-09-30 | 0.65 |
| 2016-06-30 | 0.55 |
| 2016-03-31 | 0.27 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Genomed Spólka Akcyjna will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Genomed Spólka Akcyjna's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Genomed Spólka Akcyjna has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Genomed Spólka Akcyjna performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Genomed Spólka Akcyjna has delivered over 20% year on year earnings growth in the past 5 years.
- Genomed Spólka Akcyjna's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Genomed Spólka Akcyjna's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
All data from Genomed Spólka Akcyjna Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in PLN Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 18.59 | 1.52 | 9.60 | |
| 2018-09-30 | 18.05 | 1.72 | 8.76 | |
| 2018-06-30 | 17.43 | 2.23 | 8.19 | |
| 2018-03-31 | 17.05 | 2.25 | 8.20 | |
| 2017-12-31 | 16.36 | 1.80 | 8.31 | |
| 2017-09-30 | 15.86 | 0.97 | 8.68 | |
| 2017-06-30 | 15.60 | 0.67 | 8.93 | |
| 2017-03-31 | 15.35 | 0.27 | 9.06 | |
| 2016-12-31 | 14.39 | 0.27 | 8.51 | |
| 2016-09-30 | 13.54 | 0.86 | 7.63 | |
| 2016-06-30 | 12.15 | 0.73 | 7.11 | |
| 2016-03-31 | 10.76 | 0.36 | 6.89 | |
| 2015-12-31 | 9.68 | 0.00 | 6.99 | |
| 2015-09-30 | 8.78 | -0.26 | 7.01 | |
| 2015-06-30 | 8.39 | -0.45 | 7.34 | |
| 2015-03-31 | 7.70 | -0.10 | 6.50 | |
| 2014-12-31 | 7.33 | 0.21 | 5.97 | |
| 2014-09-30 | 6.32 | -0.03 | 5.80 | |
| 2014-06-30 | 5.62 | 0.03 | 4.87 | |
| 2014-03-31 | 5.33 | -0.15 | 4.76 | |
| 2013-12-31 | 4.96 | -0.32 | 4.38 | |
| 2013-09-30 | 4.98 | -0.37 | 3.89 | |
| 2013-06-30 | 5.12 | -0.53 | 5.79 | |
| 2013-03-31 | 5.51 | -0.25 | 4.80 | |
| 2012-12-31 | 5.53 | -0.37 | 3.87 | |
| 2012-09-30 | 5.63 | -0.13 | 5.96 | |
| 2012-06-30 | 5.43 | 0.20 | 3.15 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Genomed Spólka Akcyjna has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Genomed Spólka Akcyjna used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
- Genomed Spólka Akcyjna has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Genomed Spólka Akcyjna's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Genomed Spólka Akcyjna has a total score of 4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Genomed Spólka Akcyjna's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Genomed Spólka Akcyjna's finances.
The net worth of a company is the difference between its assets and liabilities.
- Genomed Spólka Akcyjna is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Genomed Spólka Akcyjna's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Genomed Spólka Akcyjna has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Genomed Spólka Akcyjna Company Filings, last reported 4 months ago.
| Date (Data in PLN Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 7.58 | 0.00 | 3.62 |
| 2018-09-30 | 7.06 | 0.00 | 2.53 |
| 2018-06-30 | 7.06 | 0.00 | 2.94 |
| 2018-03-31 | 6.68 | 0.00 | 3.72 |
| 2017-12-31 | 6.05 | 0.00 | 3.11 |
| 2017-09-30 | 5.34 | 0.00 | 2.44 |
| 2017-06-30 | 4.83 | 0.00 | 2.94 |
| 2017-03-31 | 4.53 | 0.00 | 3.64 |
| 2016-12-31 | 4.25 | 0.00 | 2.75 |
| 2016-09-30 | 4.37 | 0.00 | 2.28 |
| 2016-06-30 | 4.16 | 0.00 | 2.41 |
| 2016-03-31 | 4.16 | 0.00 | 2.29 |
| 2015-12-31 | 3.98 | 0.00 | 2.68 |
| 2015-09-30 | 3.51 | 0.01 | 1.97 |
| 2015-06-30 | 3.43 | 0.00 | 1.04 |
| 2015-03-31 | 3.80 | 0.00 | 2.03 |
| 2014-12-31 | 3.98 | 0.00 | 2.97 |
| 2014-09-30 | 3.77 | 0.07 | 2.22 |
| 2014-06-30 | 3.88 | 0.00 | 2.86 |
| 2014-03-31 | 3.92 | 0.00 | 3.04 |
| 2013-12-31 | 3.80 | 0.00 | 1.30 |
| 2013-09-30 | 3.83 | 0.00 | 2.25 |
| 2013-06-30 | 3.88 | 0.00 | 3.19 |
| 2013-03-31 | 4.08 | 0.00 | 3.09 |
| 2012-12-31 | 4.11 | 0.00 | 2.72 |
| 2012-09-30 | 4.20 | 0.00 | 2.72 |
| 2012-06-30 | 4.41 | 0.00 | 1.22 |
- Genomed Spólka Akcyjna has no debt.
- Genomed Spólka Akcyjna had no debt 5 years ago.
- Genomed Spólka Akcyjna has no debt, it does not need to be covered by operating cash flow.
- Genomed Spólka Akcyjna has no debt, therefore coverage of interest payments is not a concern.
Financial health checks
We assess Genomed Spólka Akcyjna's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Genomed Spólka Akcyjna has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Genomed Spólka Akcyjna's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
PLN2,000 of
Genomed Spólka Akcyjna
shares you are expected to receive
PLN0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Genomed Spólka Akcyjna's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Genomed Spólka Akcyjna's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 0 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.8% |
| Poland Market Average Dividend Yield | Market Cap Weighted Average of 200 Stocks | 4.1% |
| Poland Minimum Threshold Dividend Yield | 10th Percentile | 1.5% |
| Poland Bottom 25% Dividend Yield | 25th Percentile | 2.8% |
| Poland Top 25% Dividend Yield | 75th Percentile | 7.9% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Genomed Spólka Akcyjna has not reported any payouts.
- Unable to verify if Genomed Spólka Akcyjna's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Genomed Spólka Akcyjna's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Genomed Spólka Akcyjna afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Genomed Spólka Akcyjna has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
CEO Bio
Dr. Hab. Anna Boguszewska-Chachulska, Ph.D. is a Co-founder of Genomed Spólka Akcyjna and has been its Chief Executive Officer since 2013. Dr. Hab. Boguszewska-Chachulska also serves as President of the Management Board at Genomed Spólka Akcyjna. She served as Joint Owner at Genomed Spólka Akcyjna. From 2009 to 2013, she served as Chief Operating Officer and Member of the board of Directors at Genomed Ltd and since 2011 at Genomed SA (joint-stock company). Dr. Hab. Boguszewska-Chachulska co-founded Genomed Ltd. Co in 2007. She served as Member of the Advisory Board Genomed Ltd from 2007 to 2009. Dr. Hab. Boguszewska-Chachulska was Member of Board of Directors of at Genomed Ltd since 2009. From 1996 to 1998, she led a project on plant transformation towards potato virus Y resistance financed by a grant of Polish Committee of Scientific Research. She has research training and experience at Laboratoire de Biologie Cellulaire, INRA, Versailles, France - CNRS stipend, October-December 1992, December 1993; October 1995, 1996, 1997 and EEC grant - April-June 1993, French Government stipend - July-August 1995. Dr. Hab. Boguszewska-Chachulska served as Professor at the Institute of Biotechnology, Department of Chemistry, Warsaw University of Technology from September 2009 to August 2010; Associate Professor at the Institute of Biochemistry and Biophysics since 2008; Assistant Professor at the Institute of Biochemistry and Biophysics from 1998 to 2008; Senior Research Assistant at Institute of Biochemistry and Biophysics from 1993 to 1998 and Research assistant from 1990 to 1993. From 2009 to 2010, she was Tutor of two M.Sc. and three B.Sc. students. Dr. Hab. Boguszewska-Chachulska received Polish Scientific Award of Plant Genetics - First prize for “Creative contribution to the plant molecular virology” on June 30, 1998; Award of Polish Academy of Sciences for co-authoring of a series of works dedicated to “RNA genomes of crop pathogens - structures, functions, control and spread” on November 18 1999; Award of IBB PAS for the review published in Prog. Nucleic Acid Res. Mol. Biol. 80, 135-68. “Virus-Like Particles: Models for Assembly Studies and Foreign Epitope Carriers on March 23 2006 ” and on December 04 2006 Habilitation stipend for Women in Science 2006 awarded by l’Oréal Polska with a support from Polish UNESCO Committee. Dr. Hab. Boguszewska-Chachulska Patents Obtained; P-186760 (1997), New binary vector and method of its construction P-186761 (1997) and Method of construction of plants resistant to potato virus Y (PVY). Dr. Hab. Boguszewska-Chachulska took post-doctoral training in the laboratory of Dr. Linda E. Hyman at Tulane University in New Orleans in U.S. - looking for the roles of Elongin C in yeast from August 1998 to June 2000. She is specialised in Molecular Biology. Dr. Hab. Boguszewska-Chachulska studied (B.Sc) at Biology Faculty, University of Warsaw, from 1984 to 1990; M.Sc.: Department of Genetics, University of Warsaw.; Ph.D. in Biochemistry : Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, January 1998; Habilitation in Biology Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, October 2008.
CEO Compensation
- Insufficient data for Anna to compare compensation growth.
- Insufficient data for Anna to establish whether their remuneration is reasonable compared to companies of similar size in Poland.
Management Team
Anna Boguszewska-Chachulska
Co-Founder
Marek Zagulski
Co-Founder & Member of Management Board
Andrzej Palucha
Co-Founder & Member of Management Board
Tomasz Danis
Member of Management Board
6 yrs
Board of Directors
Maciej Kowalski
Chairman of the Supervisory Board
Piotr Skowron
Member of Supervisory Board
Tomasz Bykowski
Member of Supervisory Board
Boguslaw Bobula
Member of Supervisory Board
60
Mieczyslaw Prószynski
Member of the Supervisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (PLN) | Value (PLN) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Genomed Spólka Akcyjna's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Genomed Spólka Akcyjna has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Boasting A 32% Return On Equity, Is Genomed Spólka Akcyjna (WSE:GEN) A Top Quality Stock?
Genomed Spólka Akcyjna has a ROE of 32%, based on the last twelve months. … That means that for every PLN1 worth of shareholders' equity, it generated PLN0.32 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleIs Genomed Spólka Akcyjna (WSE:GEN) Attractive At Its Current PE Ratio?
Genomed Spólka Akcyjna (WSE:GEN) is trading with a trailing P/E of 12.4x, which is lower than the industry average of 26.6x. … While GEN might seem like an attractive stock to buy, it is important to understand the assumptions behind the P/E ratio before you make any investment decisions. … Check out our latest analysis for Genomed Spólka Akcyjna
Simply Wall St - – Full articleIs Genomed Spólka Akcyjna's (WSE:GEN) 33.69% ROE Strong Compared To Its Industry?
Genomed Spólka Akcyjna (WSE:GEN) delivered an ROE of 33.69% over the past 12 months, which is an impressive feat relative to its industry average of 17.03% during the same period. … If GEN borrows debt to invest in its business, its profits will be higher. … But ROE does not capture any debt, so we only see high profits and low equity, which is great on the surface
Simply Wall St - – Full articleDoes Genomed Spólka Akcyjna's (WSE:GEN) PE Ratio Signal A Buying Opportunity?
By comparing a stock’s price per share to its earnings per share, we are able to see how much investors are paying for each dollar of the company’s earnings. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for GEN Price per share = PLN15.8 Earnings per share = PLN1.34 ∴ Price-Earnings Ratio = PLN15.8 ÷ PLN1.34 = 11.8x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … Since GEN's P/E of 11.8x is lower than its industry peers (25.4x), it means that investors are paying less than they should for each dollar of GEN's earnings.
Simply Wall St - – Full articleWhat You Must Know About Genomed Spólka Akcyjna's (WSE:GEN) ROE
See our latest analysis for Genomed Spólka Akcyjna What you must know about ROE Firstly, Return on Equity, or ROE, is simply the percentage of last years’ earning against the book value of shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Genomed Spólka Akcyjna’s equity capital deployed. … Given a positive discrepancy of 20.72% between return and cost, this indicates that Genomed Spólka Akcyjna pays less for its capital than what it generates in return, which is a sign of capital efficiency.
Simply Wall St - – Full articleCompany Info
Description
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers analysis of mutations responsible for congenital diseases in approximately 120 genes; and next generation sequencing technology. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis, and the sequencing of phage genetic material, or bacteria and yeast genomes; and next generation sequencing and genetic counseling services. Further, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through the eStore. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. Genomed Spólka Akcyjna is based in Warsaw, Poland.
Details
| Name: | Genomed Spólka Akcyjna |
| GEN | |
| Exchange: | WSE |
| Founded: | |
| PLN27,747,321 | |
| 1,321,301 | |
| Website: | http://www.genomed.pl |
| Address: |
Genomed Spólka Akcyjna ul. Ponczowa 12, Warsaw, 02-971, Poland |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| WSE | GEN | Bearer Shares | Warsaw Stock Exchange | PL | PLN | 30. May 2011 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/20 21:45 |
| End of day share price update: | 2019/05/20 00:00 |
| Last earnings filing: | 2019/02/14 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
